nacap

Sodium 2-mercaptobenzothiazole is the sodium salt of mercaptobenzothiazole, and is used as a copper corrosion inhibitor.

Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3]

Lenacapavir, also known as GS-6207, is an HIV-1 capsid inhibitor. It demonstrates an average EC50 of 50 pM (ranging from 20-160 pM) against 23 clinical isolates of HIV-1 from diverse subtypes, with tests performed in peripheral blood mononuclear cells (PBMCs). In vitro, Lenacapavir exhibits picomolar potency and shows no cross-resistance with existing antiretroviral compounds. Furthermore, Lenacapavir displays significant antiviral activity in individuals with HIV-1, regardless of prior treatment history, with no pre-existing resistance detected.

Lenacapavir pacfosacil (Example 44) is an inhibitor of viral capsid and nucleocapsid, exhibiting antiviral properties. This compound is utilized in the study of retrovirus infections, including HIV infection.

mRNACap 2'-O-methyltransferase uses S-adenosylmethionine (SAM) as a methyl donor to add a methyl group at the 2'-O position of the first nucleotide at the 5' end of Cap-0 mRNA, resulting in the formation of a Cap-1 structure. This Cap-1 structure enhances translation efficiency and boosts subsequent protein expression.